A case study on rheumatoid arthritis.
At a time when many managed care organizations increasingly shift costs to patients through tiered formularies and widening copay differentials, biologic agents represent a significant clinical and financial challenge unlikely to be managed optimally with tiered formularies and greater patient cost sharing. The information discussed in this article is intended for healthcare professionals involved with rheumatoid arthritis therapy, including but not limited to physicians in both the inpatient and outpatient setting, and for other managed care professionals, including medical directors, pharmacy directors, long-term care decision makers, nurses, pharmacists, and case managers.
Baker
Tom
T
Strategy and Analytics Practice, The Zitter Group, Millburn, New Jersey, USA.
D018501:Antirheumatic Agents / Q000145:classification / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics; D003659:Decision Making, Organizational; D016527:Drug Costs; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics / Q000627:therapeutic use; D008329:Managed Care Programs / Q000191:economics / Q000458:organization & administration*; D010358:Patient Participation; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor